CO2021017202A2 - Compuestos tricíclicos - Google Patents

Compuestos tricíclicos

Info

Publication number
CO2021017202A2
CO2021017202A2 CONC2021/0017202A CO2021017202A CO2021017202A2 CO 2021017202 A2 CO2021017202 A2 CO 2021017202A2 CO 2021017202 A CO2021017202 A CO 2021017202A CO 2021017202 A2 CO2021017202 A2 CO 2021017202A2
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
tricyclic compounds
formula
methods
acceptable salts
Prior art date
Application number
CONC2021/0017202A
Other languages
English (en)
Spanish (es)
Inventor
Sandrine Vendeville
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of CO2021017202A2 publication Critical patent/CO2021017202A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2021/0017202A 2019-05-30 2021-12-15 Compuestos tricíclicos CO2021017202A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962854597P 2019-05-30 2019-05-30
PCT/US2020/034746 WO2020243199A1 (en) 2019-05-30 2020-05-27 Tricyclic compounds

Publications (1)

Publication Number Publication Date
CO2021017202A2 true CO2021017202A2 (es) 2022-01-17

Family

ID=73552666

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017202A CO2021017202A2 (es) 2019-05-30 2021-12-15 Compuestos tricíclicos

Country Status (19)

Country Link
US (1) US11136321B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976618A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022534501A (cg-RX-API-DMAC7.html)
KR (1) KR20220016177A (cg-RX-API-DMAC7.html)
CN (1) CN113906029A (cg-RX-API-DMAC7.html)
AU (1) AU2020282707B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023967A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138938A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003139A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017202A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192760A1 (cg-RX-API-DMAC7.html)
IL (1) IL287813A (cg-RX-API-DMAC7.html)
MA (1) MA56058A (cg-RX-API-DMAC7.html)
MX (1) MX2021014458A (cg-RX-API-DMAC7.html)
PE (1) PE20220427A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552953A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113214QA (cg-RX-API-DMAC7.html)
TW (1) TW202110845A (cg-RX-API-DMAC7.html)
WO (1) WO2020243199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220000874A1 (en) * 2019-05-30 2022-01-06 Aligos Therapeutics, Inc. Tricyclic compounds
US12703701B2 (en) * 2019-12-10 2026-08-11 Shanghai Hansoh Biomedical Co., Ltd. Pyrazole-containing polycyclic derivative inhibitor, preparation method therefor and application thereof
GB202103704D0 (en) * 2021-03-17 2021-04-28 Pathios Therapeutics Ltd Compounds
WO2022115384A1 (en) * 2020-11-24 2022-06-02 Aligos Therapeutics, Inc. Tricyclic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0701273D0 (en) 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
WO2008157273A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
RU2016120763A (ru) * 2013-10-29 2017-12-05 Медивир Аб Ингибиторы респираторного синцитиального вируса
BR112018068177B1 (pt) 2016-03-09 2024-02-27 Emory University Composto, uso do composto e composição para eliminação do vírus da hepatite b com agentes antivirais
CN110066278B (zh) * 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用

Also Published As

Publication number Publication date
BR112021023967A2 (pt) 2022-03-08
MA56058A (fr) 2022-04-06
TW202110845A (zh) 2021-03-16
CL2021003139A1 (es) 2022-09-23
EP3976618A1 (en) 2022-04-06
CN113906029A (zh) 2022-01-07
EP3976618A4 (en) 2023-01-04
JP2022534501A (ja) 2022-08-01
PH12021552953A1 (en) 2022-07-25
US20200407361A1 (en) 2020-12-31
MX2021014458A (es) 2022-01-06
WO2020243199A1 (en) 2020-12-03
EA202192760A1 (ru) 2022-03-05
PE20220427A1 (es) 2022-03-29
SG11202113214QA (en) 2021-12-30
CA3138938A1 (en) 2020-12-03
AU2020282707A1 (en) 2021-12-02
AU2020282707B2 (en) 2025-06-19
US11136321B2 (en) 2021-10-05
KR20220016177A (ko) 2022-02-08
IL287813A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
CO2024001367A2 (es) Compuestos antivirales
MX2021011606A (es) Compuestos dirigidos a prmt5.
CL2021003202A1 (es) Compuestos de pirrolidina
CL2021003139A1 (es) Compuestos tricíclicos
AR116604A1 (es) Inhibidores de kras g12c
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
CO2021014210A2 (es) Compuestos de pirrol
ECSP22057865A (es) Inhibidores de formas mutantes de egfr
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
UY40470A (es) Compuestos tricíclicos y sus usos
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
AR126251A1 (es) Inhibidores de cdk2
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CL2021001461A1 (es) Moduladores de trex1
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
UY37941A (es) Derivados de bencimidazol y sus usos
MX2024011179A (es) Compuestos multiciclicos
PY2228191A (es) Nuevos derivados de heteroaril aminopropanol
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
MX2025002817A (es) Compuestos para el tratamiento del cancer
DOP2025000009A (es) Inhibidores de acc novedosos
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1